Caleb A Class
机构: Assistant Professor of Pharmaceutical Sciences, Butler University
每年引用次数
引用次数
引用: 1,485
H-指数: 20
I10-指数 : 27
出版物: 75
Can MRI help assess aggressiveness of endometrial cancer
M. Ahmed , J.F. Al-Khafaji , C.A. Class , W. Wei
Clinical Radiology 73 ( 9)
9
2018
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers
Peng DH , Rodriguez BL , Diao L , Gaudreau PO
Nat Commun.
51
2021
Overexpression of Histone Demethylase KDM6B in the Hematopoietic Compartment Promotes the Effect of Innate Immune Activation and Results in Myelodysplastic Syndrome (MDS)-like Phenotype in Mice
Yue Wei , Guillermo Garcia-Manero , Hong Zheng , Yu Jia
Blood 130 50 -50
2017
Highly-Sensitive DNA Hydroxymethylation Analysis in Myelodysplastic Syndromes (MDS)
Guillermo Garcia-Manero , Stefan Siwko , Yue Wei , Deqiang Sun
Blood 136 17 -17
2020
Hypomethylating Agents Do Not Alter Novel Splicing Events in Myeloid Neoplasms
Hussein A Abbas , Feng Wang , Yue Wei , Hui Yang
Blood 136 37 -38
2020
Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis
Rashmi Kanagal-Shamanna , Guillermo Montalban Bravo , Panagiotis Katsonis , Koji Sasaki
Blood 136 4 -5
2
2020
KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice.
Yue Wei , Hong Zheng , Naran Bao , Shan Jiang
Blood Advances 2 ( 19) 2491 -2504
12
2018
Demographic, clinical and geographical factors associated with lack of receipt of recommended chemotherapy.
Parijatham S. Thomas , Caleb Class , Tanmay Gandhi , Arvind Bambhroliya
Journal of Clinical Oncology 36 ( 15_suppl) e13563 -e13563
2018
Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
Rashmi Kanagal-Shamanna , Guillermo Montalban-Bravo , Caleb Class , Koji Sasaki
Blood 134 1719 -1719
2019
Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome
Ali Sakhdari , Caleb Class , Guillermo Montalban-Bravo , Koji Sasaki
Blood 134 3016 -3016
2019
Comprehensive DNA 5-Hydroxymethylation Landscapes in Myelodysplastic Syndromes (MDS)
Jia Li , Yue Wei , Minjung Lee , Caleb Class
Blood 134 2996 -2996
2019
Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
Guillermo Montalban-Bravo , Elias Jabbour , Caleb Class , Nicholas J. Short
Blood 134 1715 -1715
1
2019
KDM6B Overexpression and TET2 Deficiency Cooperatively Drive Development of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-like Phenotype in Mice
Yue Wei , Hong Zheng , Naran Bao , Rashmi Kanagal-Shamanna
Blood 134 562 -562
2
2019
Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes
Guillermo Montalban-Bravo , Rashmi Kanagal-Shamanna , Christopher B. Benton , Caleb Class
Blood 134 1711 -1711
1
2019
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
Irene Ganan-Gomez , Hui Yang , Feiyang Ma , Guillermo Montalban-Bravo
Nature medicine 28 ( 3) 557 -567
12
2022
P-106: Targeting DNA2 overcomes myeloma cells’ metabolic reprogramming in response to DNA damage
Natthakan Thongon , Andrea Santoni , Jintan Lui , Natalia Baran
Clinical Lymphoma Myeloma and Leukemia 21 S96 -S97
2021
From Quantum Chemistry to Diesel Injector Deposits: Revisiting Liquid Phase Oxidation
Amrit Jalan , Jorge Aguilera-Iparraguirre , Ionut M Alecu , Joshua W Allen
Sulfur group type response to an oxidative desulfurization treatment
Michael T Timko , Ezequial Schmois , Pushkaraj Patwardhan , Yulko Kida
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 245
2013
Low-dose decitabine versus low-dose azacitidine in lower-risk MDS
Koji Sasaki , Elias Jabbour , Guillermo Montalban-Bravo , Faezeh Darbaniyan
NEJM evidence 1 ( 10) EVIDoa2200034 -EVIDoa2200034
17
2022
Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes
Ali Sakhdari , Caleb Class , Guillermo Montalban-Bravo , Koji Sasaki
Modern Pathology 35 ( 9) 1212 -1219
9
2022
Guillermo Garcia-Manero William H. Green Kim-Anh Do Koji Sasaki (佐々木 宏治) Irene Ganan-Gomez Michael Timko Christopher B Benton Connie W. Gao Christopher Reddy Hector H. Hernandez Robin Bonomi Robert K. Nelson Shamel Merchant Adam Carr Jorge Aguilera-Iparraguirre Mengjie Liu Aäron Vandepute Lawrence Lai Priya Bhosale Michael Andreeff